Milan Jaros / Bloomberg via Getty Images Shares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...